scholarly journals Incidence of triple negative breast cancer at Rajendra Institute of Medical Sciences, Ranchi

2019 ◽  
Vol 6 (9) ◽  
pp. 3134
Author(s):  
Priyanka Kumari ◽  
Sumit Bhaskar ◽  
Rajiv Ranjan ◽  
Dipendra Kumar Sinha
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tumour Size ◽  
Progesterone Receptors ◽  
Prognostic Index ◽  
Axillary Lymph ◽  
Receptor Status ◽  
Her 2

Background: Breast carcinoma is the second most common carcinoma in women and accounts for 22% of all female cancer, which is more than twice the prevalence of cancer in women at any other site. Triple negative breast cancer, i.e., negative expression of oestrogen and progesterone receptors and HER2/neu receptors and accounts for approximately 10-17% of all breast carcinomas, is biologically aggressive, resistant to conventional cytotoxic chemotherapy treatment, and is associated with reduced survival compared to other subtypes of breast cancer.Methods: History, local examination, Various investigations like: FNAC of breast lump and axillary lymph node, USG of breasts and axilla, USG of whole abdomen and pelvis, Chest X-ray PA View etc, ER/PR and HER-2/neu status on the specimen sent for HPE were done. The prognostic implications on ER, PR and HER-2/neu receptors were assessed indirectly with the help of Nottingham prognostic index (NPI)).Results: A statistically significant correlation of ER/PR receptor status was found with tumour size, no. of lymph nodes, tumour grade and NPI, whereas HER2/neu receptor status had a statistically significant correlation with tumour size and no. of lymph node involved. Incidence of triple negative breast cancer in this Institute is 20%.Conclusions: ER, PR and HER2/neu receptor status is highly important predictor in cases of carcinoma breast which necessitates routine evaluation of these receptor statuses for better management of disease.

scholarly journals Mixed Effects and Mechanisms of Cannabinoids for Triple-Negative Breast Cancer Treatment

2021 ◽  
Author(s):  
Khanh Tran
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Antitumor Effects ◽  
Current Therapies ◽  
Cancer Types ◽  
Her 2 ◽  
Tumour Activity

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the lack of estrogen receptors (ER), progesterone receptors, and HER-2 receptors. Thus, TNBC tumours do not benefit from the current therapies targeting ER or HER-2. Therefore, there is an urgent need to develop novel treatment for this subtype of breast cancer. Marijuana is a common name given to Cannabis plants, a group of plants in the Cannabis genus of the Cannabaceae family. Cannabis plants are among the oldest cultivated crops, traced back at least 12,000 years and are well known for their multi-purpose usage, including medicinal purposes. The main active compounds extracted from Cannabis plants are 21-carbon-containing terpenophenolics, which are referred to as phytocannabinoids. Of these, the tetrahydrocannabinol (THC) group contains highly potent cannabinoids, including delta-9-tetrahydrocannabinol (∆9-THC) and delta-8-tetrahydrocannabinol (∆8-THC), which are the most abundant THCs and are largely responsible for psychological and physiological effects of marijuana. The use of Cannabis plants for medicinal purposes was first recorded in 2337 BC in China, where Cannabis plants were used to treat pains, rheumatism, and gout. Recently, several cannabinoids have been approved for a number of treatments, one of which is the treatment of nausea and vomiting caused by chemotherapy in cancer patients. Furthermore, increasing evidence shows that cannabinoids not only attenuate side effects due to cancer treatment, but might also potentially possess direct antitumor effects in several cancer types, including breast cancer. However, anti-tumour activity of marijuana has been variable in different studies and even promoted tumour growth in some cases. In addition, the mechanisms of cannabinoid action in cancer remain unclear. This review summarizes evidence about the mixed actions of cannabinoids in cancer in general and triple-negative breast cancer in particular.

Triple negative breast cancer in a South African urban breast care centre.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13067-e13067
Author(s):  
Leanne Prodehl ◽  
Carol Benn
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
South African ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tumour Size ◽  
Pathological Response ◽  
Advanced Stage ◽  
Complete Pathological Response ◽  
Breast Care

e13067 Background: Triple negative breast cancer (TNBC) is associated with advanced stage at presentation, aggressive tumour biology and poor outcomes. There is no published data for South Africa. Methods: A retrospective file review of TNBC cases at the Milpark Breast Care Unit in Johannesburg, South Africa, data were collected on presentation, treatment and outcomes. A prospective file review and telephonic interview were done for further follow up. Results: There were 196 patients with TNBC identified out of 1407 patients (13.9%), 135 patients were analysed. Stage at presentation was IIa and IIb in approximately half (46.7%) of the patients and IIIa, IIIb and IV in a third (31.8%). Patients presented with large tumours -71.8% were T2 to T4; and lymph node positive disease (55.6%). The majority of patients had high-grade, poorly differentiated tumours. The challenges when treating TNBC were reflected in the use of multimodality therapy; 92.2% of patients had chemotherapy, as neoadjuvant (59.3%), adjuvant or both. There were 93 (68.9%) patients treated with adjuvant radiation therapy. If neoadjuvant chemotherapy was given 91.2% had a response. Recurrences occurred in 33 patients, with a 5-year disease free survival of 72.5%, and preponderance to visceral metastases (45.2%). Recurrences occurred early, the median was 23.1 months and all had occurred within eight years. Younger patients (HR 1.58), tumour size and lymph node positivity (HR 4.42) were associated with increased risk of recurrence, but only lymph node positivity was significant (HR 4.42). Complete pathological response to neoadjuvant chemotherapy was associated with fewer recurrences if no tumour was found in either the breast or the lymph nodes (HR 0.33). The 5-year overall survival was 76.4%. There was no significant difference in survival for age, node status, nuclear grade, or complete pathological response, only tumour size at presentation was significantly associated. Conclusions: The prevalence of triple negative breast cancer in a South African breast care unit was similar to some European studies but less than studies in West and East Africa. Patients presented at an advanced stage and had poorer outcomes than luminal breast cancers.

scholarly journals Mucinous Cystadenocarcinoma in Breast: Complicated with Lymph Node, Thoracic Wall Metastasis, and Contralateral Triple Negative Breast Cancer: A Case Report

2021 ◽  
Author(s):  
Zhenyu Li ◽  
Qingming Jiang ◽  
Dongfang Guo ◽  
Yong Cao ◽  
Yangling Peng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Mucinous Cystadenocarcinoma ◽  
Thoracic Wall ◽  
Her 2 ◽  
Severe Atypia ◽  
Columnar Cells

Abstract Background: Mucinous cystadenocarcinoma of the breast is a very rare and special type adenocarcinoma of the mammary tract. We report a rare case of mucinous cystadenocarcinoma of the breast with an unfavourable prognosis which was confirmed after surgical resection pathologically. Case summary: At low power appearance, the tumor formed mucus-filled spaces of varying sizes, and with mucus-rich tumor cells lining the walls. The tumor cells were arranged in papillary structures. At high magnification, the tumor cells shown moderate to severe atypia, which were most of simple columnar cells with nuclei in the base and cytoplasm rich in mucin. In some areas, tumor cells proliferated, stratified, and clustered that protruded into the cyst cavity, or formed papillary structures with thin fibrovascular core. Immunohistochemical staining showed cytoplasm CK7 strong positive of tumor cells and cytoplasm negative of CK20, PAX-8 and CDX2, which could exclude metastatic tumors from ovary and intestine. And the tumor cells also demonstrated the basal-like characters such as negative for ER, PR, HER-2 (triple-negative), CK5/6 focal positive, EGFR positive. Besides, a triple negative breast cancer with basal-like features, lymph node, thoracic wall metastasis of mucinous cystadenocarcinoma was found. Conclusion: Mucinous cystadenocarcinoma of the breast usually have a favorable prognosis, but in this case, it happened lymph node, thoracic wall metastasis, therefore, it needs extra attention of clinical workers.

HER-2, Hormone Receptors, and clinicopathologic characteristics in Uruguayan breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22202-e22202
Author(s):  
L. B. Delgado ◽  
R. Fresco ◽  
G. Santander ◽  
S. Aguiar ◽  
N. Camejo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Triple Negative ◽  
Histologic Grade ◽  
Her2 Status ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Axillary Lymph Node Status ◽  
Her 2

e22202 Background: Few Latin-American studies and none Uruguayan study have evaluated HER-2, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer (BC). The purpose of the study was to investigate the frequency of these markers and the relationship between them and with clinicopathologic features in Uruguayan BC patients (pts). Methods: We retrospectively reviewed clinical records from pts who underwent curative surgery for stage I-III invasive BC at the Oncology Units of 4 institutions in Montevideo between march 2006 and march 2008. We obtained the following data: age, TNM, ER/PR status by immunohistochemistry (IHC) and HER2 status by IHC and FISH in HER2 IHC 2+. Fisher's exact test was used to analyze the data. Results: 427 pts were included. Median age was 60 years-old (range: 24–93 y), postmenopausal 75%, stages: I 33%, II 42%, III 23%, unknown 2%. ER/PR status was known in 94,6% of cases: ER+/PR+ 66,1%, ER+/PR- 11,1%, ER-/PR+ 3,5%, ER-/PR- 19,3%. HER2 status was known in 47% (199/427) of cases, being positive (IHC 3+ or FISH+) in 13.6%. Triple negative tumors were found in 32 of 199 pts (16%). HER2 was positive in 8% of pts with ER+ and/or PR+ tumors, and in 18% of pts with ER-PR- disease (p=0.08). We did not find a significant association between axillary lymph node status and HER2 status. Besides, triple negative BC did not correlate with axillary lymph node status. When analized by menopausal status, the frequency of triple negative pts was 14% in the premenopausal group and 4% in the postmenopausal group (p=0.005). In addition, the rate of triple negative BC was 0% in pts with histologic grade 1 and 10% in pts with histologic grade 2–3 (p = 0.0005). Conclusions: Our data from Uruguayan pts show a lower prevalence of HER2 positive but a similar prevalence of ER+ and PR+ operable BC than the prevalence reported in most American and European studies. In accordance with previous reports, triple negative BC correlated with younger age and higher histologic grade. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document